Coherus Biosciences Reports Third Quarter 2024 Financial Results And Provides Business Update
Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA® net revenue, quarter-over-quarter – – UDENYCA labeling and pac ...
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 6, 2024 Coherus BioSciences, Inc. beats earnings expectations. Reported EPS is $-0.01, expectations were $-0.1. Operator: Good day, and thank you for standing ...
WATTAgNet3d
Think strategically in developing IBDV vaccination programs
Developing a vaccination program for infectious bursal disease virus (IBDV) challenges should consider the severity and ...
eLife9d
Periosteal skeletal stem cells can migrate into the bone marrow and support hematopoiesis after injury
Skeletal stem cells have been isolated from various tissues, including periosteum and bone marrow, where they exhibit key functions in bone biology and hematopoiesis, respectively. The role of ...
Enzo Biochem Reports Revenue Growth Despite Losses
Enzo Biochem ( (ENZ) ) has realeased its Q4 earnings. Here is a breakdown of the information Enzo Biochem presented to its investors. Enzo ...
eLife6d
MuSK-BMP signaling in adult muscle stem cells maintains quiescence and regulates myofiber size
A central question in adult stem cell biology is elucidating the signaling pathways regulating their dynamics and function in diverse physiological and age-related contexts. Muscle stem cells in ...
TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 millionRaises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 ...
Dupixent® (Dupilumab) Approved In The European Union As The First And Only Medicine For Young Children With Eosinophilic Esophagitis
Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological <a target=_blank ...
AZoLifeSciences on MSN8d
Enhancing Vaccine Design with Proteomic Data
Antibody proteomics advances vaccine research, revealing immune responses and identifying proteins essential for developing effective vaccines against diseases.